Rena Schindler

Rena (Jeffrey) Schindler has a diverse work experience spanning over several years. They currently work as a Principal Scientist in Flow Cytometry at Orna Therapeutics since March 2022. Prior to that, Rena worked at AVROBIO from 2019 to 2022, initially as a Scientist and later as a Senior Scientist. At AVROBIO, Rena played a key role in developing and optimizing SOPs for pivotal studies, training scientists, and collaborating on various projects related to gene therapy. They also prepared manuscripts and conference presentations.

Before joining AVROBIO, Rena served as a Postdoctoral Research Fellow at Massachusetts General Hospital from 2016 to 2018. During this time, they focused on the role of the transcription factor TEL in both normal and malignant hematopoiesis. They also investigated clinically relevant mutations and the fusion protein TEL-AML1 in leukemia. Prior to that, Rena worked at Agios Pharmaceuticals as a Scientist, conducting molecular and cell biology studies related to cancer drug targets and mechanisms.

Rena's career began at Boston Children's Hospital in 2002, where they worked as a Research Technician studying hematopoiesis and transcription factors. They also gained experience as a Research Technician at Massachusetts General Hospital and as a Clinical Research Technician at Shaare Zedek Medical Center, Jerusalem.

During their time at the Massachusetts Institute of Technology (MIT), Rena held multiple roles, including Postdoctoral Researcher and Graduate Research Assistant. They also served as a Graduate Teaching Assistant for Introduction to Experimental Biology and Communication. Overall, Rena's work experience showcases their expertise in flow cytometry, gene therapy, hematopoiesis, cancer research, and teaching.

Rena (Jeffrey) Schindler completed their Bachelor's Degree in Biology at The Hebrew University of Jerusalem from 2000 to 2002. Rena (Jeffrey) then pursued a Doctor of Philosophy (Ph.D.) in Molecular Biology at the Massachusetts Institute of Technology from 2007 to 2015.